News
A breakthrough to reduce risk of HIV in adolescents and adults weighing at least 35 kg. WHO releases the new guidelines ...
The World Health Organization now recommends lenacapavir, a twice-yearly injectable HIV prevention drug, especially for high-risk groups. This endorse ...
As expected, the new recommendations that the World Health Organization (WHO) issued for HIV and sexually transmitted ...
Even with the HIV prevention waters now dominated by Gilead Science’s Yeztugo (lenacapavir), Merck & Co. is not afraid to swim deeper in. | Even with the HIV prevention waters now dominated by Gilead ...
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the ...
The WHO’s Director-General described the policy guidelines for Gilead’s twice-yearly drug as the “next best thing” in the ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Gilead researchers and collaborators will present new Phase 3 ...
For the second time this year, Leo Pharma has struck a partnership with a major drugmaker, this time paying Boehringer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results